Product References — Single Donor Human Complement Serum

Human CTLA4-Ig therapy can give false-positive anti-pig antibody results in primates after xenotransplantation

Posted by Corey Marcath on

Human CTLA4-Ig therapy can give false-positive anti-pig antibody results in primates after xenotransplantation

Single Donor Human Complement Serum from Innovative Research was used in the following study:   Human CTLA4-Ig therapy can give false-positive anti-pig antibody results in primates after xenotransplantation Qi Li, Takayuki Yamamoto, Hayato Iwase, Huy Quoc Nguyen, Yi Wang, David Ayares, David K.C.Cooper, Hidetaka Hara Transplant Immunology December 2019 “…Background: Measurement of serum anti-pig antibodies is an important parameter in immune monitoring after pig-to-nonhuman primate xenotransplantation. Pig aortic endothelial cells (pAECs) are commonly used for this purpose. However, human (h) CTLA4-Ig (abatacept/belatacept) could bind to pCD80/86 on the cells, and a secondary antibody (i.e., anti-human IgG) may recognize hCTLA4-Ig (in...

Read more →

CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica

Posted by Leanne Kodsmann on

CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica

Human Complement from Innovative Research was used in the following study:   CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica Lukmanee Tradtrantip, Tianjiao Duan, Michael R. Yeaman, Alan S. Verkman Journal of Neuroinflammation December 2019, 16:57 "... Neuromyelitis optica spectrum disorder (herein called NMO) is an inflammatory demyelinating disease that can be initiated by binding of immunoglobulin G autoantibodies (AQP4-IgG) to aquaporin-4 on astrocytes, causing complement-dependent cytotoxicity (CDC) and downstream inflammation. The increased NMO pathology in rodents deficient in complement regulator protein CD59 following passive transfer of AQP4-IgG has suggested the potential therapeutic utility...

Read more →

Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica

Posted by Leanne Kodsmann on

Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica

Human Complement from Innovative Research was used in the following study:   Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica Tianjiao Duan, Alex J. Smith and Alan S. Verkman Journal of Neuroinflammation, October 2018 "... Specified concentrations of AQP4-IgG (or control human IgG, Thermo Fisher Scientific, Rockford, IL) and human complement (Innovative Research, Novi, MI) were added in Hank’s buffer, and cells were incubated at 37 °C for specified times. In some experiments, cells were exposed to serum of an AQP4-IgG seropositive NMO patient who met the revised diagnostic criteria for clinical disease. A fixable dead-cell stain (amine-reactive dye,...

Read more →

Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth

Posted by Leanne Kodsmann on

Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth

Human Complement Serum from Innovative Research was used in the following study:   Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth Xun Ma, Sandy W. Wong, Ping Zhou, Chakra P. Chaulagain, Parul Doshi, Andreas K. Klein, Kellie Sprague, Adin Kugelmass, Denis Toskic, Melissa Warner, Kenneth B. Miller, Lisa Lee, Cindy Varga and Raymond L. Comenzo Experimental Hematology & Oncology, October 2018 "... Complement-rich human serum (CRHS) was from Innovative Research (Novi, MI), was aliquoted, cryopreserved and thawed for immediate use. For CDC studies, cells were aliquoted at 4 × 105 per well,...

Read more →

Human Complement Serum - May 31, 2017

Posted by Leanne Kodsman on

May 31, 2017 Innovative Research's Single Donor Human Complement Serum was recently used in the following study: Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis opticaLukmanee Tradtrantip, Xiaoming Yao, Tao Su, Alex J. Smith, Alan S. Verkman - Acta Neuropathologica, 2017 ... Complement dependent cytotoxicity Specified concentrations of AQP4-IgG (or control human IgG, Thermo Fisher Scientific, Rockford, IL) and human complement (Innovative Research, Novi, MI) were added in Hank's buffer, and cells were incubated at 37 °C for specified times. ...

Read more →